DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Articles in academic journal >

Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan


File Description SizeFormat
BMCGas16_82.pdf590.73 kBAdobe PDFView/Open

Title: Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan
Authors: Takeshima, Fuminao / Yoshikawa, Daisuke / Higashi, Syuntaro / Morisaki, Tomohito / Oda, Hidetoshi / Ikeda, Maho / Machida, Haruhisa / Matsushima, Kayoko / Minami, Hitomi / Akazawa, Yuko / Yamaguchi, Naoyuki / Ohnita, Ken / Isomoto, Hajime / Ueno, Masato / Nakao, Kazuhiko
Issue Date: 29-Jul-2016
Publisher: BioMed Central
Citation: BMC Gastroenterology, 16, 82; 2016
Abstract: Background: There are few reports of the efficacy of adalimumab (ADA) for clinical remission and preventing postoperative recurrence in Crohn's disease (CD) in Asian real practice settings. We conducted a Japanese multicenter retrospective observational study. Methods: We evaluated patients with CD who were treated with ADA at 11 medical institutions in Japan to investigate the clinical efficacy of remission up to 52 weeks and the associated factors to achieve remission with a CD Activity Index (CDAI) < 150. The effects of preventing postoperative recurrence were also evaluated. Results: In 62 patients, the remission rates were 33.9, 74.2, 75.8, 77.4, and 66.1 % at 0, 4, 12, 26, and 52 weeks, respectively. Although 10 patients discontinued treatment due to primary nonresponse, secondary nonresponse, or adverse events, the ongoing treatment rate at 52 weeks was 83.9 %. Comparison of remission and non-remission on univariate analysis identified colonic type and baseline CDAI value as significant associated factors (P < 0.05). In 16 patients who received ADA to prevent postoperative recurrence, the clinical remission maintenance rate was 93.8 % and the mucosal healing rate was 64.3 % during a mean postoperative follow-up period of 32.3 months. Conclusions: ADA effectively induced remission and prevented postoperative recurrence in patients with CD in a real practice setting.
Keywords: Adalimumab / Crohn’s disease / Preventing postoperative recurrence / Japanese patients / Real practice
URI: http://hdl.handle.net/10069/36911
DOI: 10.1186/s12876-016-0501-9
Rights: © 2016 The Author(s). / This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Type: Journal Article
Text Version: publisher
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/36911

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace